摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-2,8-dimethyl-5-[2-(4-trifluoromethylphenyl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 1061352-52-0

中文名称
——
中文别名
——
英文名称
trans-2,8-dimethyl-5-[2-(4-trifluoromethylphenyl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
英文别名
2,8-dimethyl-5-[(E)-2-(4-trifluoromethylphenyl)vinyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;trans-2,8-dimethyl-5-[4-(trifluoromethyl)styryl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;2,8-dimethyl-5-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
trans-2,8-dimethyl-5-[2-(4-trifluoromethylphenyl)ethenyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole化学式
CAS
1061352-52-0
化学式
C22H21F3N2
mdl
——
分子量
370.417
InChiKey
LZUIBAORLZILET-FMIVXFBMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    27
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    8.2
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
    申请人:Ivachtchenko Alexandre Vasilievich
    公开号:US20190233409A1
    公开(公告)日:2019-08-01
    The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof wherein R 1 is C 1 -C 5 alkyl; R 2 , is independently hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2,3, or 4; Ar is unsubstituted phenyl or substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle one or, with two nitrogen atoms in the heterocycle; excluding the compounds of the formulas A1-A4 The invention relates to the novel chemical compounds, methods for their preparation and use as antagonists of 5-HT 6 receptors, simultaneously regulating homeostasis of calcium ions in cells. The invention relates to the novel annelated azaheterocycles—2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, to methods for their preparation, to pharmaceutical compositions, including these compounds as active substances, and to methods of treatment and profylaxis of various diseases.
    本发明涉及公式1.2的化合物,或其药学上可接受的盐或水合物,其中R1为C1-C5烷基;R2独立地为氢、卤素、C1-C3烷基、CF3、OCF3或OCH3;i为1、2、3或4;Ar为未取代的苯基或取代的苯基,取代基为卤素、C1-C6烷基、C1-C6烷氧基、取代氨基或三氟甲基;或Ar为取代或未取代的6元芳杂环之一,其中异杂环中含有两个氮原子;但不包括A1-A4式的化合物。本发明涉及新的化学化合物、其制备方法以及作为5-HT6受体拮抗剂的用途,同时调节细胞内钙离子的稳态。本发明涉及新的螺合的氮杂环-2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物,以及其制备方法、包括这些化合物作为活性物质的制药组合物,以及各种疾病的治疗和预防方法。
  • SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
    申请人:Alla Chem, LLC
    公开号:US20130217703A1
    公开(公告)日:2013-08-22
    The present invention relates to a method of antagonizing a 5-HT 6 serotonin receptor and simultaneously regulating Ca +2 ion homeostasis in a cell, comprising administering to the cell a compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: R 1 is a C 1 -C 5 alkyl; R 2 i is independently hydrogen, halogen, a C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle; and W is an ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to new compounds selected from the group of compounds of the general formula 1, method for their preparation, pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease, or obesity in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1 according to claim 1 , or a pharmaceutically acceptable salt thereof.
    本发明涉及一种拮抗5-HT6 5-羟色胺受体和同时调节细胞内Ca+2离子稳态的方法,包括向细胞中投与式1的化合物或其药学上可接受的盐,其中:R1是C1-C5烷基;R2独立地是氢、卤素、C1-C3烷基、CF3、OCF3或OCH3;i为1、2、3或4;Ar是未取代的苯基或取代的苯基,其被卤素、C1-C6烷基、C1-C6烷氧基、取代的氨基团或三氟甲基取代;或Ar是带有一个或两个氮原子的取代或未取代的6元芳香杂环;W是乙烯基—CH2—CH2—、乙烯基—CH═CH—或乙炔基—C≡C—。本发明还涉及从式1的化合物组中选择的新化合物、其制备方法、制备药物组合物的方法以及治疗认知障碍或神经退行性疾病或肥胖症的方法,包括向需要治疗的受体中投与式1的化合物或其药学上可接受的盐的有效剂量。
  • SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF
    申请人:Alla Chem, LLC.
    公开号:EP2145887B1
    公开(公告)日:2016-04-27
  • Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof
    申请人:Ivashchenko Andrey Alexandrovich
    公开号:US20100120792A1
    公开(公告)日:2010-05-13
    The invention relates to antagonists of serotonin 5-HT 6 receptors simultaneously regulating homeostasis of Ca +2 ions in cells, representing substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles of the general formula 1, pharmaceutically acceptable salts and/or hydrate thereof. In the general formula 1: R 1 represents amino group substituent selected from optionally substituted C 1 -C 5 alkyl; R 2 , is one or more substituents selected from hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 ; Ar is phenyl optionally substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group, or CF 3 ; or optionally substituted aromatic 6-membered heterocycle comprising 1-2 nitrogen atoms in the cycle; W represents ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to the novel compounds selected from the compounds of the general formula 1, methods for their preparation, pharmaceutical compositions and methods of their use.
  • US8541437B2
    申请人:——
    公开号:US8541437B2
    公开(公告)日:2013-09-24
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐